CXC chemokine ligand 4 (CXCL4) is predictor of tumour angiogenic activity and prognostic biomarker in non-small cell lung cancer (NSCLC) patients undergoing surgical treatment

Biomarkers. 2016 Jul;21(5):474-8. doi: 10.3109/1354750X.2016.1172111. Epub 2016 Apr 21.

Abstract

Objective: To evaluate the association of CXC chemokine ligand 4 (CXCL4) plasma levels with tumour angiogenesis in non-small cell lung cancer (NSCLC) and to assess association of CXCL4 with clinical outcomes.

Patients and methods: Fifty patients with early stage NSCLC who underwent pulmonary resection. CXCL4 levels were analysed by ELISA. Angiogenesis was assessed by immunohistochemistry, and microvessel density (MVD) count.

Results: There was positive correlation between MVD and CXCL4 levels. Patients with higher CXCL4 levels had worse overall and disease-free survival.

Conclusions: Plasma levels of CXCL4 are associated with tumour vascularity. Increased CXCL4 levels in NSCLC patients undergoing treatment may indicate active cancer-induced angiogenesis associated with relapse and worse outcome.

Keywords: Angiogenesis; CXC chemokine ligand 4; chemokines; non-small cell lung cancer; platelet factor 4.

Publication types

  • Observational Study

MeSH terms

  • Biomarkers / blood
  • Carcinoma, Non-Small-Cell Lung / diagnosis*
  • Carcinoma, Non-Small-Cell Lung / surgery
  • Disease-Free Survival
  • Humans
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / surgery
  • Neoplasm Recurrence, Local
  • Neovascularization, Pathologic
  • Platelet Factor 4 / blood*
  • Treatment Outcome

Substances

  • Biomarkers
  • Platelet Factor 4